# Immucell Corp (ICCC)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/immucell-corp/ JSON: https://steadybase.io/company/immucell-corp.json Checked Nov 10, 2026. Latest filing read: Aug 13, 2026.

## Company

- Legal name: IMMUCELL CORP /DE/
- Ticker: ICCC (Nasdaq)
- SEC CIK: 0000811641
- Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Headquarters: Portland, ME
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: immucell.com
- LinkedIn: https://www.linkedin.com/company/immucell
- Next earnings date: Nov 13, 2026

## Key facts

- Revenue: $27.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/0001437749-26-010339-index.html
- Operating income: $1.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/0001437749-26-010339-index.html
- Net income: -$1.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/0001437749-26-010339-index.html
- SG&A: $6.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/0001437749-26-010339-index.html
- Employees: 73 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/iccc20251231_10k.htm
- Shares outstanding: 9,082,197 as of Jul 31, 2026 (10-Q filed Aug 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926027668/0001437749-26-027668-index.html
- Auditor: Wipfli LLP, Radnor, Pennsylvania, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/iccc20251231_10k.htm

## Business

ImmuCell Corporation, founded in 1982 and a SEC-registered public company since 1987, is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. The Company's practical, science-based solutions help prevent calf scours, one of the most prevalent diseases in neonatal calves worldwide that accounts for 30-40% of pre-weaning mortality in many production systems.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/iccc20251231_10k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $27.6M | $1.6M | -$1.0M | $6.8M |
| Dec 31, 2024 | $26.5M | -$1.6M | -$2.2M | $5.7M |
| Dec 31, 2023 | $17.5M | -$5.7M | -$5.8M | $5.2M |
| Dec 31, 2022 | $18.6M | -$2.3M | -$2.5M | $5.5M |
| Dec 31, 2021 | $19.2M | $257,385 | -$78,292 | $4.2M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/immucell-corp.json

## Officers and directors

- Boekhorst Paul Francis Olivier te, President and CEO. Source: Form 4 filed Jun 22, 2026, https://www.sec.gov/Archives/edgar/data/811641/000143774926021258/0001437749-26-021258-index.htm
- chief financial officer, chief financial officer. Source: 10-K filed Mar 30, 2026, https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/iccc20251231_10k.htm
- Bobbi Jo Brockmann, VP of Sales and Marketing. Source: Form 4 filed Apr 14, 2026, https://www.sec.gov/Archives/edgar/data/811641/000143774926012234/0001437749-26-012234-index.htm
- ANTHONY A. DIMARCO, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/811641/000143774926013234/iccc20260420_def14a.htm
- DAVID S. TOMSCHE, D.V.M., Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/811641/000143774926013234/iccc20260420_def14a.htm
- GILLES GUILLEMETTE, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/811641/000143774926013234/iccc20260420_def14a.htm
- KATHY V. TURNER, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/811641/000143774926013234/iccc20260420_def14a.htm
- Michael F. Brigham, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/811641/000143774926013234/iccc20260420_def14a.htm
- PAUL OLIVIER TE BOEKHORST, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/811641/000143774926013234/iccc20260420_def14a.htm
- PAUL R. WAINMAN, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/811641/000143774926013234/iccc20260420_def14a.htm

## Recent 8-K events

- Oct 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926032465/iccc20261009_8k.htm
- Aug 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926027667/iccc20260808_8k.htm
- Jul 9, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926023199/iccc20260708_8k.htm
- Jun 17, 2026: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926020926/iccc20260615_8k.htm
- Jun 10, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926020154/iccc20260608_8k.htm
- May 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926017049/iccc20260512_8k.htm
- May 8, 2026: Item 1.01, Entry into a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/iccc20260508_8k.htm
- Apr 14, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926012182/iccc20260413_8k.htm
- Apr 8, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926011757/iccc20260408_8k.htm
- Mar 18, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926008842/iccc20260318_8k.htm

## Insider trades (Form 4)

- Jun 18, 2026: Boekhorst Paul Francis Olivier te (President and CEO) bought 8,000 shares, about $76,000. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926021258/0001437749-26-021258-index.htm
- Dec 3, 2025: Boekhorst Paul Francis Olivier te (President and CEO) bought 9,785 shares, about $48,584. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774925036794/0001437749-25-036794-index.htm
- Nov 25, 2025: David Scott Tomsche (Director) bought 3,266 shares, about $15,562. Source: https://www.sec.gov/Archives/edgar/data/811641/000143774925036477/0001437749-25-036477-index.htm

## What management said

- "Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase compared to the three months ended September 30, 2025. Domestic sales were $6.9 million, a 29.2% increase compared to 2025" Timothy Fiori, Chief Financial Officer of ImmuCell (8-K filed Oct 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/811641/000143774926032465/ex_1024934.htm

## Latest filings

- 8-K filed Oct 13, 2026: https://www.sec.gov/Archives/edgar/data/811641/000143774926032465/iccc20261009_8k.htm
- 10-K filed Mar 30, 2026: https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/iccc20251231_10k.htm
- 10-Q filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/811641/000143774926027668/iccc20260801_10q.htm
- DEF 14A filed Apr 24, 2026: https://www.sec.gov/Archives/edgar/data/811641/000143774926013234/iccc20260420_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/